Navigation Links
MIT researchers see alternative to common colorectal cancer drug
Date:6/17/2008

A compound that accumulates in cells more readily than a commonly used colorectal cancer drug may be just as useful in treating colorectal tumors, but with fewer side effects, MIT researchers have found.

Both compounds are analogues of cisplatin, a potent anticancer agent, but the newly investigated compound, known as cDPCP, may better target colorectal cells, potentially sparing other body tissues from damage.

"This compound, the antitumor properties of which were established in mice over 20 years ago, emerged in our search for platinum anticancer drug candidates with cellular uptake properties analogous or superior to those of oxaliplatin," said Stephen Lippard, the Arthur Amos Noyes Professor of Chemistry at MIT and senior author of a paper on the work appearing in the June 16 online edition of the Proceedings of the National Academy of Sciences.

cDPCP could become an alternative to oxaliplatin, which was approved by the FDA in 2004 and is usually the first therapeutic line of defense against colorectal cancer. More than 100,000 Americans are diagnosed with colorectal cancer every year, making it the fifth most common cancer in the United States, according to the National Cancer Institute.

Oxaliplatin and cisplatin fight tumors by entering the cell nucleus and binding to DNA, damaging it and inducing cell death, said Ryan Todd, a graduate student in chemistry and co-lead author of the paper.

cDPCP kills cells in a similar way. However, the key difference is that while oxaliplatin and cisplatin can enter almost any cell, causing harmful side effects, cDPCP requires the assistance of organic cation transporters (OCTs) embedded in the cell membrane.

That help is required because cDPCP is a positively charged molecule. Working with cultured human cells, the researchers found that cDPCP engages the assistance of OCT1 and OCT2, which are present in the colon. Thus, cDPCP could be specifically targeted to colorectal tumors.

"cDPCP may affect other cells in the body, but there could be greater targeting of colorectal cancer cells because of uptake by the transporters," said graduate student Katherine Lovejoy, co-lead author of the paper.

cDPCP's anticancer activity was first observed in mice 20 years ago, but it was never tested in humans, in part because it was not expected to readily cross cell membranes.

Researchers in Lippard's lab, working with other cancer researchers at MIT, have started studying the effectiveness of cDPCP in mice expressing human colorectal tumors, and they also hope to launch clinical trials in humans.


'/>"/>

Contact: Teresa Herbert
therbert@mit.edu
617-258-5403
Massachusetts Institute of Technology
Source:Eurekalert

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
4. Bipolar disorder relapses halved by Melbourne researchers
5. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
6. High and mighty: first common height gene identified by researchers behind obesity gene finding
7. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
8. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
9. Researchers develop long-lasting growth hormone
10. Jefferson immunology researchers halt lethal rabies infection in brain
11. Purdue researchers develop technology to detect cancer by scanning surface veins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 26, 2017 , ... ... a new educational seminar to focus on current legislative activity and the latest ... begin at 1 p.m. Sunday, Sept. 10, and will continue through Monday, Sept. ...
(Date:5/26/2017)... ... May 26, 2017 , ... A new analysis of community ... healthiest seniors are located in the Midwest. With the average cost of healthcare rising ... are concerned with both the quality and affordability of where they live. An annual ...
(Date:5/26/2017)... BOSTON, MA (PRWEB) , ... May 26, 2017 , ... ... Care Act (AHCA), which narrowly passed the U.S. House on May 4, would result ... would be expected under continued implementation of the 2010 Patient Protection and Affordable Care ...
(Date:5/26/2017)... ... 2017 , ... Silver Birch of Hammond, a new assisted lifestyle community, has ... acres of land at 5620 Sohl Avenue in Hammond, serves older adults who need ... studio and one-bedroom apartments. Each of the private apartments at Silver Birch features a ...
(Date:5/26/2017)... ... May 26, 2017 , ... “When the Stars Lead Home”: a poignant story ... published author Laura Weigel Douglas, an avid reader who lives in the Pacific Northwest ... feels like Green Hills Adventure Camp. She couldn’t be more grateful. , Twelve-year old ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... May 9, 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... clinical-stage pharmaceutical company focused on the development of ... Canadian Intellectual Property Office has granted Oramed a ... of Exenatide". The patent covers Oramed,s invention of ... GLP-1 is an incretin hormone that stimulates the ...
(Date:5/6/2017)... , May 5, 2017   Provista , a proven ... than 200,000 customers, today announced Jim Cunniff as ... of executive and business experience to Provista, including most recently ... in California . He assumed his new ... is a great fit for Provista," says Jody Hatcher ...
(Date:5/4/2017)...  A recent study published in the American ... as a means of disinfection anesthesia workstations ... on anesthesia workstations. In the study, UVC disinfection ... equipment surfaces contaminated with three (3) organisms commonly ... further validates the body of literature supporting Tru-D," ...
Breaking Medicine Technology: